Daratumumab combined with dexamethasone and lenalidomide or bortezomib in relapsed/refractory multiple myeloma (RRMM) patients: Report from the multiple myeloma GIMEMA Lazio group

The multiple myeloma (MM) treatment has changed over the last years due to the introduction of novel drugs. Despite improvements in the MM outcome, MM remains an incurable disease. Daratumumab is a human IgGK monoclonal antibody targeting CD38 with tumor activity associated with immunomodulatory mec...

Descripción completa

Detalles Bibliográficos
Autores principales: Fazio, Francesca, Franceschini, Luca, Tomarchio, Valeria, Rago, Angela, Garzia, Maria Grazia, Cupelli, Luca, Bongarzoni, Velia, Andriani, Alessandro, Gumenyuk, Svitlana, Tafuri, Agostino, Siniscalchi, Agostina, Piciocchi, Alfonso, De Fabritiis, Paolo, De Rosa, Luca, Caravita di Toritto, Tommaso, Annibali, Ombretta, Cantonetti, Maria, Petrucci, Maria Teresa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Haematologic Malignancy ‐ Plasma Cell
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9175681/
https://www.ncbi.nlm.nih.gov/pubmed/35846211
http://dx.doi.org/10.1002/jha2.359

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9175681/
https://www.ncbi.nlm.nih.gov/pubmed/35846211
http://dx.doi.org/10.1002/jha2.359

Ejemplares similares